Definium Therapeutics, Inc.
NASDAQ:DFTXBiotechnology
-$0.41 today
- Market cap
- $3.99B
- Beta
- 2.38
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.18
Volume 1.91M
Average 2.67M
DFTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Definium Therapeutics, Inc.NASDAQ: DFTX
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents rises 1108.2% from a year ago
Cash & equivalents stood at $241.15M at the end of Q3 FY2026, up 1108.2% from a year earlier and down 63.2% from the prior quarter. Over 3 fiscal years it compounded at +22.0% a year.
Context
- Cash & equivalents amounted to 22.4% of total assets at the end of Q3 FY2026, up 14.0 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +1108.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 257.84M USD
- Year-over-year change
- -5.8%
- 4-year CAGR
- +17.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 257.84M | -5.8% |
| FY2024 | 2024-12-31 | 273.74M | +174.6% |
| FY2023 | 2023-12-31 | 99.7M | -29.9% |
| FY2022 | 2022-12-31 | 142.14M | +6.4% |
| FY2021 | 2021-12-31 | 133.54M | — |
Cash & Equivalents vs competitors
How DFTX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1108.2% is the 3rd highest of 11, against a peer median of +49.8%.
- Cash & equivalents amounts to 22.4% of total assets for DFTX, versus a peer median of 61.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $24.65B USD | +161575.2% | +31.6% | 25.9% | |
| Sep 2026 | $361.85M USD | +142.0% | +79.7% | 27.6% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $320.68M USD | +2154.3% | +126.9% | 81.5% |
| Jun 2026 | $319.85M USD | +5.6% | +17.2% | 42.0% | |
| Mar 2026 | $263.76M USD | +64.1% | +54.0% | 95.5% | |
| Mar 2026 | $242.65M USD | -0.9% | +14.1% | 88.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $241.15M USD | +1108.2% | +22.0% | 22.4% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $147.07M USD | +15.9% | -8.8% | 95.6% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $78.06M USD | +35.5% | +19.1% | 15.7% |
| Mar 2026 | $55.71M USD | +11.1% | +19.1% | 13.3% | |
| Dec 2025 | A$49.15M AUD | +983.5% | -1.6% | 86.4% | |
| Peer median (excluding DFTX) | — | +49.8% | +19.1% | 61.8% | |
Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 133.54M | 142.14M | 99.7M | 273.74M | 257.84M |
| Short-term Investments | 0 | 0 | 0 | 0 | 153.76M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 4.17M | 7.88M | 7.73M |
| Total Current Assets | 137.22M | 146.06M | 103.87M | 281.62M | 419.32M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M |
| Intangible Assets | 6.87M | 3.69M | 527K | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 331K | 224K | 613K | 862K |
| Total Non-current Assets | 26.79M | 23.94M | 20.67M | 20.53M | 20.78M |
| Total Assets | 164M | 169.99M | 124.54M | 302.15M | 440.1M |
| Account Payables | 4.18M | 2.11M | 4.14M | 2.01M | 5.35M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.3M | 13.03M | 20.74M | 30.42M | 61.35M |
| Total Current Liabilities | 10.41M | 17.89M | 32.25M | 38.85M | 66.7M |
| Long-term Debt | 0 | 0 | 14.13M | 21.85M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.93M | 1.18M | 32K | 0 | 41.08M |
| Total Non-current Liabilities | 1.93M | 1.18M | 14.16M | 21.85M | 41.08M |
| Total Liabilities | 12.34M | 19.08M | 46.41M | 60.7M | 107.77M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (137.67M) | (194.47M) | (290.2M) | (398.88M) | (582.67M) |
| Accumulated OCI | 1.05M | 627K | 343K | 819K | 1.09M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 151.66M | 150.92M | 78.13M | 241.45M | 332.33M |
| Total Debt | 0 | 72K | 14.13M | 21.85M | 0 |
| Net Debt | (133.54M) | (142.07M) | (85.58M) | (251.89M) | (257.84M) |
Definium Therapeutics, Inc.
NASDAQ:DFTX
Intrinsic Alpha fair value
Locked
Current Price
$29.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.